2025 has been an active year with the participation of RADeep members at the Data Access Committee at Vall d’Hebron and the presentation of abstracts at the 67th ASH Annual Meeting and Exposition.

L’aportació permet avançar en estudis de referència internacional i continuar millorant l’atenció dels infants trasplantats de fetge.

Since 2019, Pulseras Candela has been collaborating with the Childhood Cancer and Hematological Diseases group at VHIR on the project “New Therapeutic Approaches for the Treatment of Pediatric Ependymoma.”

The jury has awarded a scientific infrastructure that redefines urban integration, sustainability and collaboration in the Vall d'Hebron.

The session has helped bring the public an up-to-date perspective on diagnosis, treatments, and the research lines that are transforming the future of patients.

The study, conducted with more than 1,400 people with addictive disorders, delves into the biological mechanisms that connect mental health, life trajectory and educational opportunities.

The study will be conducted in the Intensive Care Medicine Service of the Vall d’Hebron University Hospital and will validate the prognostic value of the NLRP3 biomarker.

The donation will boost several lines of research to advance liquid biopsy in pediatric sarcomas and brain tumors.

More than 50 healthcare professionals and community agents in Benguela receive specialized training to improve the detection and support of women with perinatal disorders.

A sessions brought together expertise, frontier projects and new perspectives to move towards more transformative and people-centered research.

The new edition, led by Dr. Marc Miravitlles, updates treatment recommendations and integrates the consensus of the main medical societies involved in chronic obstructive pulmonary disease (COPD).

The work, awarded €25,000, studies respiratory syncytial virus (RSV) variants in children following the introduction of nirsevimab.

Experts addressed the main current and future challenges to improve therapeutic options for patients with this type of tumor.

ImmunoPET enables in vivo detection of LIF expression, a molecule linked to tumour growth, immune evasion and treatment resistance.

According to the results, the team highlights the need to use combinations of drugs to reactivate all HIV reservoirs and eliminate the virus from the different tissues where it remains silent.

SOFA-2 is being updated after thirty years to incorporate advances in diagnosis, monitoring and life support.

This tool will help avoid invasive techniques and assist in selecting candidates for clinical trials of new treatments.

The VHIR researcher has been awarded a research grant on bioethics and the inclusion of chromosomal sex in healthcare.

Dr. Xavier Montalban, Dr. Álex Rovira, Dr. Mar Tintoré and Dr. Jaume Sastre Garriga have been recognised in the listing.

The clinical trial, which also involved Vall d’Hebron, shows that the new therapy improves survival by 86% in patients with thymidine kinase 2 deficiency (TK2d).

The project aims to improve prevention, diagnosis, and treatment through computational biomedicine, innovative therapies, and the transfer of knowledge into clinical practice.

The European project DISCOvERIE, led by Vall d’Hebron, paves the way for more personalized diagnoses and new treatment strategies to improve patients’ quality of life.

The Stroke Research and the Neurovascular Diseases groups lead innovative research projects in both clinical and translational areas.

The study analyzes the cost-effectiveness and environmental impact of reusable trocars compared to single-use trocars in laparoscopic surgery.